ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY-Reference-Cited by-同舟云学术

ALLOGENEIC HEMATOPOIETIC TRANSPLANTATION AS ADOPTIVE IMMUNOTHERAPY

Published:1999-10 Issue:5 Volume:13 Page:1041-1057
ISSN:0889-8588
Container-title:Hematology/Oncology Clinics of North America
language:en
Short-container-title:Hematology/Oncology Clinics of North America

Author:

Champlin Richard,Khouri Issa,Kornblau Steven,Marini Frank,Anderlini Paolo,Ueno Naoto T.,Molldrem Jeffrey,Giralt Sergio

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference113 articles.

1. Toxicity and efficacy of defined doses of CD4+ donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant;Alyea;Blood,1998

2. Graft-versus-leukemia: No longer an epiphenomenon;Antin;Blood,1993

3. Cytokine dysregulation and acute graft-versus-host disease;Antin;Blood,1992

4. Bone marrow transplantation for patients with chronic myeloid leukaemia: T-cell depletion with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukaemic relapse;Apperley;Bone Marrow Transplant,1986

5. Philadelphia-positive metaphases in the marrow after bone marrow transplantation for chronic granulocytic leukemia;Apperley;Am J Hematol,1986

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Infections in Hematopoietic Stem Cell Transplant Recipients;Infectious Diseases;2017

2. Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo;Leukemia;2016-03-08

3. Allogeneic Stem Cell Transplantation for Multiple Myeloma;Hematology/Oncology Clinics of North America;2014-10

4. Early administration of donor lymphocyte infusions upon molecular relapse after allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia: a study by the Chronic Malignancies Working Party of the EBMT;Haematologica;2014-07-04

5. The cyclin dependent kinase inhibitor (R)-roscovitine mediates selective suppression of alloreactive human T cells but preserves pathogen-specific and leukemia-specific effectors;Clinical Immunology;2014-05